Paz-Ares L, Dvorkin M, Chen Y, et al. – Via performing a randomized, open-label, phase 3 trial at 209 sites across 23 countries that included adults with untreated extensive-stage small-cell lung cancer (ES-SCLC), experts evaluated durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment-naive people with ES-SCLC. Study participants had WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, and were allocated to durvalumab plus platinum–etoposide (n = 268) and platinum–etoposide groups (n = 269). Overall, in people with ES-SCLC compared with a clinically significant control group, the investigators noted that overall survival was significantly enhanced by first-line durvalumab plus platinum–etoposide, and safety findings were consistent with the known safety profiles of all drugs received.